Paul Liknaitzky
Head of the Clinical Psychedelic Lab and Senior Research Fellow in the Department of Psychiatry at Monash University
Data updated
Research Footprint
Paul Liknaitzky appears in 8 tracked papers (2021–2025), most studied alongside Psilocybin, LSD and DMT, across Anxiety Disorders, Depressive Disorders and Substance Use Disorders (SUD).
Most-cited paper: Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice (79 citations).
Frequent co-authors: Vince Polito, Richard Chambers and David Yaden.
Background & Research
Dr Paul Liknaitzky is Head of the Clinical Psychedelic Lab and a Senior Research Fellow in the Department of Psychiatry at Monash University. His work focuses on novel applications of psychedelic therapies, translating evidence into clinical practice, examining risks, improving therapist training, and expanding access and affordability. He has led pioneering studies in psychedelic-assisted treatment, including early trials in anxiety, therapist training, and psychedelic-augmented virtual reality.
Key Impact
He is a leading Australian psychedelic researcher who has helped establish clinical psychedelic research infrastructure and conducted several world-first psilocybin studies.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Paul Liknaitzky is associated with.